我何时才能恢复正常?卵巢癌一线化疗后持续症状与不良身心状态的轨迹及预测因素
在OPAL研究中,527例接受至少3周期一线化疗的卵巢癌女性于化疗结束时至结束后6周内完成基线患者报告结局问卷,并在基线后3、6、9、18个月随访。基线时57%报告中度至重度疲乏、22%焦虑、20%抑郁、14%临床失眠、45%生活质量显著低于一般人群;50%至75%的个体报告结局在6个月内恢复正常(情绪健康除外,为42%),但约五分之二女性在18个月时仍有至少一项持续不良。
要点
- 基线时57%有中度至重度疲乏,45%生活质量显著低于一般人群。
- 6个月内50%至75%的个体报告结局恢复正常,情绪健康仅42%。
- 约五分之二女性在18个月时仍有至少一项持续不良报告结局。
核心结论
- 约五分之二女性在完成卵巢癌初始治疗后可能永远无法完全恢复正常。
- 有危险因素者应被分诊接受早期支持性干预。
研究设计与样本
- OPAL(卵巢癌预后与生活方式)研究分析,纳入527例接受至少3周期一线化疗并在化疗结束时至结束后6周内完成患者报告结局问卷的女性。
- 患者报告结局指标包括焦虑、抑郁、失眠、疲乏和健康状况(生活质量),在基线及基线后3、6、9、18个月评估。
- 采用基于组的轨迹模型识别遵循相似模式的个体集群,并用逻辑回归和Cox回归分别识别与持续症状和延迟恢复相关的因素。
主要发现
- 基线时57%女性报告中度至重度疲乏,22%焦虑,20%抑郁,14%临床失眠,45%生活质量评分显著低于一般人群。
- 50%至75%的个体患者报告结局评分在6个月内恢复正常,但情绪健康例外,仅42%恢复正常。
- 约五分之二女性在18个月时仍有至少一项持续不良的患者报告结局。
- 基线症状更严重、更年轻或有焦虑/抑郁史的女性更可能出现持续症状或延迟恢复。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: After treatment for ovarian cancer, women want to know when they will feel 'normal' again. Our objective was to document the proportions of women with high levels of physical and emotional symptoms at the end of treatment, determine if/when they return to normal and identify groups at risk of persistent symptoms/delayed recovery. METHODS: Women in the OPAL (Ovarian cancer Prognosis And Lifestyle) study who received ≥3 cycles of first-line chemotherapy and completed patient-reported outcome (PRO) questionnaires on or < 6 weeks after completing chemotherapy (baseline) were included in this analysis (n = 527). PRO measures included anxiety, depression, insomnia, fatigue and wellbeing (quality-of-life) at baseline, 3, 6, 9 and 18 months post-baseline. Group-based trajectory models identified clusters of individuals who followed similar patterns. Logistic and Cox regression identified factors associated with persistent symptoms and delayed recovery, respectively. RESULTS: At baseline, 57% of women reported moderate-to-severe fatigue, 22% anxiety, 20% depression, 14% clinical insomnia and 45% had quality-of-life scores significantly lower than the general population. Between 50 and 75% of individual PRO scores normalised within six months, with the exception of emotional wellbeing (42%), but approximately two-in-five women still had at least one persistently poor PRO at 18 months. Women with more severe symptoms at baseline, who were younger, or had a history of anxiety/depression were more likely to have persistent symptoms or delayed recovery. CONCLUSIONS: Two-in-five women might never fully return to 'normal' after completing primary treatment for ovarian cancer. Those with risk factors should be triaged for early supportive interventions.
引用
- Beesley VL, Webber K, Nagle CM, et al. When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer. Gynecol Oncol. 2020. PMID: 32773150. doi:10.1016/j.ygyno.2020.07.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。